RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial

This study was funded by CARsgen Therapeutics Co., Ltd.PMID:37680942 | PMC:PMC10480529 | DOI:10.1016/j.eclinm.2023.102175

Source: Cancer Control - September 8, 2023 Category: Cancer & Oncology Authors: Qihan Fu Yi Zheng Weijia Fang Qingwei Zhao Peng Zhao Lulu Liu You Zhai Zhou Tong Hangyu Zhang Meihua Lin Xudong Zhu Huamao Wang Yumeng Wang Zhen Liu Daijing Yuan Xuanwen Bao Wanwan Gao Xiaomeng Dai Zonghai Li Tingbo Liang Source Type: research